CJC-1295 + Ipamorelin: Why It's the Canonical Growth Hormone Research Stack

The combination of CJC-1295 and Ipamorelin is the single most-used peptide stack in growth-hormone research. It has appeared in published protocols for over two decades, and the reason it works is not marketing — it's receptor biology. CJC-1295 and Ipamorelin act on completely different GH-releasing pathways that, when fired together, produce GH release that exceeds the additive sum of each peptide alone.

This guide explains why the stack outperforms monotherapy, how the two peptides combine pharmacologically, and what a protocol-ready research schedule looks like.

Mechanism: Two Independent Release Triggers

CJC-1295 — GHRH Pathway (Pulse Amplitude)

CJC-1295 is a modified growth-hormone-releasing hormone (GHRH) analog. The pituitary gland has a dedicated GHRH receptor that, when activated, increases the amplitude of endogenous GH pulses. Each pulse that the pituitary would have fired naturally becomes larger.

Two CJC-1295 variants exist:

• CJC-1295 without DAC — ~30-minute half-life. Requires 2–3 daily injections for sustained effect.
• CJC-1295 with DAC (Drug Affinity Complex) — ~6–8 day half-life via albumin binding. Weekly injection produces multi-day GH/IGF-1 elevation.

Most research stacking protocols use the no-DAC variant for tighter timing control alongside Ipamorelin.

Ipamorelin — Ghrelin Pathway (Pulse Frequency)

Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist. Unlike GHRH, the ghrelin receptor triggers GH pulses at moments the pituitary otherwise would not fire. Ipamorelin adds frequency — more pulses — rather than amplifying existing ones.

Ipamorelin is distinguished from earlier ghrelin mimetics (GHRP-6, Hexarelin) by its selectivity. It produces clean GH release without significantly affecting cortisol, prolactin, or appetite — which makes it the cleanest research tool for isolating GH-mediated effects from stress-axis confounders. See Ipamorelin vs GHRP-6 head-to-head for the selectivity comparison.

Why Combined Release Exceeds the Sum

The two pathways gate GH release independently. When only the GHRH signal fires (CJC-1295 alone), pulse amplitude increases but frequency is limited by endogenous ghrelin rhythm. When only the ghrelin signal fires (Ipamorelin alone), pulse frequency increases but amplitude is limited by endogenous GHRH tone.

When both signals fire simultaneously, the pituitary releases GH in pulses that are both larger AND more frequent than either peptide could produce alone. Published data from human studies in the 2000s and 2010s consistently shows the combined protocol producing ~1.5–2× the total GH release of matched-dose monotherapy.

This synergy is why the stack — not either peptide alone — is the research default for protocols studying GH-mediated anabolism, lean tissue accretion, and IGF-1 response biology.

Standard Dosing Protocol

Research protocols converge on:

Most researchers use 100 mcg of each at matched timing — injected together 20–30 minutes before the chosen research window. For higher-throughput protocols, 200 mcg Ipamorelin alongside 100 mcg CJC-1295 is common.

Reconstitution Math

For a 5 mg vial + 2 mL BAC water (2.5 mg/mL concentration):

• 100 mcg = 0.04 mL = 4 units on a U-100 insulin syringe

This small volume is why 2–3× daily dosing is practical — the actual injection is tiny.

Timing Within the Day

The two most common research-protocol timings:

Protocol A — Pre-Sleep + Post-Workout - Injection 1: 20–30 min before bed - Injection 2: within 15 min post-workout

Aligns with two of the largest endogenous GH pulses — the early deep-sleep pulse and the exercise-induced pulse. Most efficient 2×/day protocol.

Protocol B — 3× Daily (Every 4 Hours) - Morning: upon waking (pre-food) - Afternoon: ~6 hours later - Evening: 20–30 min pre-sleep

Captures more GH pulses across the day. Standard for protocols that need sustained GH elevation (e.g., 24-hour IGF-1 response studies).

Critical rule: no food 20–30 minutes before or after injection. Elevated blood glucose and free fatty acids both blunt the pituitary GH response. Fasted-state administration is standard.

Cycle Length

The canonical cycle structure:

• 8–12 weeks on, 4 weeks off — the most common research-protocol length. Captures sustained IGF-1 elevation and tissue-accretion endpoints without triggering receptor desensitization.
• 12-week maximum — the ghrelin receptor shows measurable desensitization past this window in published data. The 4-week off period restores baseline receptor sensitivity.

Shorter cycles (4–6 weeks) are appropriate for acute-response research where the primary endpoint is dose-response characterization rather than sustained elevation.

What To Measure

Research protocols studying the CJC-1295 + Ipamorelin stack typically track:

• Serum IGF-1 — the primary downstream marker; slow-responding, averages over 1–2 weeks of GH exposure
• 24-hour GH pulse characterization — via frequent (every 10–20 min) blood sampling if the protocol has resources for it
• Body composition (DEXA) — lean mass + fat mass changes, typically measured at baseline and 8–12 weeks
• Fasting insulin + glucose — GH elevation can drive modest insulin resistance; worth tracking
• Sleep architecture — slow-wave sleep correlates with endogenous GH release; research often finds improvements with pre-sleep dosing

Common Stack-Protocol Mistakes

1. 1Using CJC-1295 with DAC alongside Ipamorelin — the multi-day CJC half-life produces continuous GH elevation, which blunts Ipamorelin's pulse-frequency contribution. No-DAC is the correct pairing.
2. 2Eating within 30 minutes of injection — glucose and fatty acids blunt the pituitary response. Fasted administration only.
3. 3Stacking with high-dose GHRP-6 or Hexarelin — adds cortisol and prolactin effects that confound GH isolation. If non-Ipamorelin ghrelin mimetics are needed, run as a separate protocol.
4. 4Not cycling off — 12+ weeks continuous use produces ghrelin-receptor desensitization. 4-week breaks preserve long-term effectiveness.
5. 5Dosing below 100 mcg per peptide — sub-threshold for clean GH-pulse generation in published research.

Stack Extensions

Researchers studying broader anabolic or recovery biology often extend the stack:

The Recomp Stack bundles GH secretagogues with metabolic partners — see the stacks range for pre-assembled protocol kits.

Shop the Canonical GH Stack

Both compounds are in stock across our brand tiers:

• CJC-1295 (no DAC) 5mg — Supreme Biologics, FourNines, Wolf
• Ipamorelin 5mg — Supreme Biologics, FourNines, Wolf

For the full mechanism comparison, see CJC-1295 vs Ipamorelin explained, or the individual glossary entries at CJC-1295 and Ipamorelin.

All products mentioned are chemical reagents intended exclusively for in-vitro research and laboratory use. Not for human consumption. Dosing and timing summaries are synthesized from published research literature; they do not constitute human therapeutic advice.